RECRUITING

Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

Talk to us

Conditions

Neurodegenerative DiseasesParkinson DiseaseParkinson Disease Psychosis

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-\[18F\]MH.MZ in both populations.

Official Title

Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

Quick Facts

Study Start:2023-01-23
Study Completion:2025-08
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05357612

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:50 Years to 85 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patient arm - clinical diagnosis of Parkinson disease, diffuse Lewy body disease, multiple systems atrophy, Huntington's Disease, Frontotemporal Dementia, and other variants
  2. * Healthy arm - age and gender matched to patient arm
  3. * Psychosis (presence of hallucinations or delusions) starting after the diagnosis of Parkinson's disease, occurring at least weekly for 4 weeks, severe enough to warrant treatment.
  4. * Study partner available for study visits
  1. * Prior stroke or other uncontrolled serious neurological or medical illness
  2. * Contra-indication or inability to tolerate MRI scan
  3. * Use of serotonergic medications in the last 6 weeks
  4. * Incapable of providing independent consent.
  5. * Pregnant or breastfeeding women
  6. * psychosis due to a metabolic, toxic, or primary psychiatric disease
  7. * Deemed unable to complete neurocognitive testing
  8. * For PD Participants: current or prior use of pimavanserin
  9. * Use of antipsychotics in the last 2 weeks

Contacts and Locations

Study Contact

Jason Elenberger, MS
CONTACT
6158751257
jason.elenberger@vumc.org
Katie Hay, MS
CONTACT
kaitlyn.r.hay@vumc.org

Principal Investigator

Daniel Claassen, MD
PRINCIPAL_INVESTIGATOR
Vanderbilt University Medical Center
Ciaran Considine, PhD
PRINCIPAL_INVESTIGATOR
Vanderbilt University Medical Center
Richard Darby, MD
PRINCIPAL_INVESTIGATOR
Vanderbilt University Medical Center

Study Locations (Sites)

Vanderbilt University Medical Center
Nashville, Tennessee, 37212
United States

Collaborators and Investigators

Sponsor: Vanderbilt University Medical Center

  • Daniel Claassen, MD, PRINCIPAL_INVESTIGATOR, Vanderbilt University Medical Center
  • Ciaran Considine, PhD, PRINCIPAL_INVESTIGATOR, Vanderbilt University Medical Center
  • Richard Darby, MD, PRINCIPAL_INVESTIGATOR, Vanderbilt University Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-01-23
Study Completion Date2025-08

Study Record Updates

Study Start Date2023-01-23
Study Completion Date2025-08

Terms related to this study

Additional Relevant MeSH Terms

  • Neurodegenerative Diseases
  • Parkinson Disease
  • Parkinson Disease Psychosis